This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.

A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-κB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.

Methods for rapidly concentrating a food sample for efficient detection of bacteria are disclosed. A microfiltration approach followed by centrifugation was used to concentrate the cells with an enzyme (e.g., a protease) added at the beginning of the process to facilitate more efficient micro-filtering. The enzyme was found to have no significant effect on cell viability.

Nonwoven articles for detecting microorganisms or cellular analytes in a fluid sample are provided. The nonwoven article includes a fibrous porous matrix and concentration agent particles enmeshed in the fibrous porous matrix. The fibrous porous matrix generally consists of inorganic fibers and polymeric fibers. Methods of detecting microorganisms or cellular analytes in a fluid sample are also provided. The method includes providing the nonwoven article, providing a fluid sample suspected of containing at least one microorganism strain or target cellular analyte, contacting the fluid sample with the nonwoven article such that at least a portion of the at least one microorganism strain or target cellular analyte is bound to the nonwoven article, and detecting the presence of bound microorganism strain(s) or bound cellular analyte(s).

Longer chain antigenic O-polysaccharide chains for use as a hapten in conjugate vaccines can be produced in a controlled manner using recombinant Gram-negative bacteria that overexpress native or heterologous genes of the wzz family, for example wzzB. Bacteria expressing a chosen wzz gene have modified O-polysaccharide chain lengths, allowing the bacteria to produce lipopolysaccharides having the longer O-polysaccharides. The LPS produced by the bacteria can be hydrolyzed to form core-O-polysaccharide molecules that can be conjugated to a carrier molecule, for example flagellin, to produce a vaccine. The invention also provides recombinant bacteria producing the longer chain O-polysaccharides, the polysaccharide molecules, themselves, conjugated vaccines comprising the O-polysaccharides, pharmaceutical compositions and kits.

The present invention provides a set of oligonucleotides to screen for the presence of targeted Salmonella serotypes in enrichment or to characterize presumptive colonies. The set of oligonucleotides includes at least one set of primers and probe for the detection of Salmonella serotype selected from Newport, Heidelberg, Infantis, and Hadar and to discriminate between. These new markers can be used after the initial screening assay described herein as a discrimination assay to differentiate S. Heidelberg from S. Infantis and S. Hadar from S. Newport.

Phage φ241 specific for Escherichia coli O157:H7 was isolated from an industrial cucumber fermentation where both acidity (pH≦3.7) and salinity (≧5% NaCI) were high. A method for preparing a food item at least substantially free of Escherichia coli O157:H7 contamination contacted the food item with a bacteriophage φ241 under conditions for the bacteriophage φ241 to lyse all or substantially all the Escherichia coli O157:H7 present in the food item, while Escherichia coli strains other than O157:H7 were not affected. A method for detecting the presence of Escherichia coli O157:H7 by contacting a bacteriophage φ241 with a food item is also disclosed.

Antimicrobial compositions derived from edible plant sources such as essential oils, their active components, spices and plant extracts have shown antimicrobial effects against a number of foodborne pathogens. The foodborne pathogens of concern in meat and poultry products include Salmonella enterica, Escherichia coli O157:H7 and Listeria monocytogenes. The antimicrobial compositions were applied to a meat surface using liquid or powder electrostatic spray systems to effectively reduce the amount of pathogens on various meat and poultry products.

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

Abstract The disclosure relates to a composition one, two or more immunogenic bacterial polypeptides and multivalent and monovalent vaccine compositions comprising the immunogenic bacterial polypeptides.

A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.

The present invention relates methods of reducing fecal shedding of animals infected with Salmonella by use of a vaccine or immunogenic composition of Salmonella Choleraesuis-Typhimurium.

There are provided novel synthetic stool preparations comprising a mixture of four intestinal bacterial strains, originally isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of use of the synthetic stool preparations are also provided.

Provided is an application of a genetic engineering bacterium of attenuated Salmonella typhimurium in preparation of medicine for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methionine synthase gene. Also provided is a construction method for the bacterium.

A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETC. Cells and vaccines obtainable by the above methods.

The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Figure 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in Figure 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

The present invention discloses a method and a highly efficient reagent to detect products derived from glucuronide metabolites presents in a sample, comprising the steps of adding to said sample an enzyme with β-glucuronidase activity originated from genus Brachyspira or any variant or mutant derived thereof; incubating the sample with the enzyme during a determined period of time; and detecting the product derived from glucuronide metabolite by means of a suitable technique. The reagent of the present invention comprises an enzyme with β-glucuronidase activity originated from genus Brachyspira or any variant or mutant derived thereof; and a suitable vehicle.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

The present invention pertains to a composition comprising mycelium of Agaricus Blazei Murill and an agent affecting bacteria belonging to Enterobactenaceae. The composition has a positive effect on the shedding of bacteria of the Enterobactenaceae, in particular of Salmonella and/or Escherichia. Moreover, the composition is effective against resistant bacteria of the Enterobacteriaceae.

Nonwoven articles for detecting microorganisms or cellular analytes in a fluid sample are provided. The nonwoven article includes a fibrous porous matrix and concentration agent particles enmeshed in the fibrous porous matrix. The fibrous porous matrix generally consists of inorganic fibers and polymeric fibers. Methods of detecting microorganisms or cellular analytes in a fluid sample are also provided. The method includes providing the nonwoven article, providing a fluid sample suspected of containing at least one microorganism strain or target cellular analyte, contacting the fluid sample with the nonwoven article such that at least a portion of the at least one microorganism strain or target cellular analyte is bound to the nonwoven article, and detecting the presence of bound microorganism strain(s) or bound cellular analyte(s).

Resumen de: WO2018038614A1

The present invention pertains to a method to control the presence of bacteria that belong to the group of enterobacteriaceae, for example Salmonella and/or Escherichia species in a monogastric animal, by feeding the monogastric animal with a feed material that comprises mycelium of Agaricus Blazei Murril (ABM mycelium), e.g., grown on a grain substrate.